All In Biotech

Drug Trial Radar · NCT02899936

Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis

Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis

Last checked: Nov 19, 2026Latest source record: Dec 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 23,789 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

23,789

Actual

Start

Jul 2016

Primary completion

Apr 27, 2017

Study completion May 31, 2018

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Case Western Reserve University; Indian Council of Medical Research
First posted
Sep 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB, DA) in infected and uninfected individuals in a community in 5 different countries. The objective is to acquire safety, efficacy, and acceptability data to assess the safety and acceptability of the IDA drug combination.

Conditions

  • Lymphatic Filariasis

Interventions

  • 3 drug dose - IDADrug

    Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)

  • 2 drug dose - DADrug

    Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by modified CTCAE v4.0 scaleTime frame: within 7 days of drug administration

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Ministere de la Sante Publique et de la Population

    Port-au-Prince, Haiti

  • Vector Control Research Centre

    Puducherry, India

  • Universitas Indonesia

    Jakarta, Indonesia

  • Papua New Guinea Institute for Medical Research

    Madang, Papua New Guinea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.